AngioDynamics (ANGO) vs MiMedx Group (MDXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AngioDynamics (ANGO) has outperformed MiMedx Group (MDXG) over the past year, losing 9.5% versus a loss of 54.9%. Over five years, MDXG leads with a -58.6% price change compared with -60.3% for ANGO. AngioDynamics is the larger company by market cap ($454.6 million vs $445.1 million), about 1.0 times the size, while MiMedx Group is growing revenue faster (+20.0% vs +9.5%).
MiMedx Group converts more of its revenue into profit, with a net margin of 11.6% versus -11.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANGO | MDXG |
|---|---|---|
| Share price | $10.81 | $3.05 |
| Market cap | $454.61M | $445.07M |
| 1-day change | +0.46% | -1.93% |
| YTD return | -15.81% | -54.95% |
| 1-year return | -9.54% | -54.88% |
| 5-year return | -60.29% | -58.62% |
| Forward P/E | — | 122.00 |
| EPS (TTM) | $-0.78 | $-0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $320.17M | $418.63M |
| Revenue growth (YoY) | +9.46% | +19.99% |
| Net income (latest FY) | $-36.74M | $48.58M |
| Gross margin | 54.62% | 82.56% |
| Operating margin | -12.47% | 15.26% |
| Net margin | -11.48% | 11.60% |
| 52-week high | $16.29 | $7.45 |
| 52-week low | $9.39 | $3.03 |
| Distance from 52-week high | -33.64% | -59.06% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +82.70% | +129.51% |
| Average volume | 651.16K | 1.39M |
| Shares outstanding | 42.05M | 145.93M |
| Employees | 632 | 808 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANGO has outperformed MDXG by 45.3 percentage points over the past year.
- MiMedx Group is more profitable, keeping 11.6 cents of every revenue dollar as net income versus -11.5 cents for AngioDynamics.
- MiMedx Group grew revenue faster in its latest fiscal year (+19.99% vs +9.46%).
About AngioDynamics
ANGO stock →AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments.
Health Care · Medical/Dental Instruments · 632 employees
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
ANGO vs MDXG FAQ
Which is bigger, AngioDynamics or MiMedx Group?
AngioDynamics (ANGO) is larger, with a market capitalization of $454.61M compared with $445.07M for MiMedx Group (MDXG).
Which stock has performed better over the past year, ANGO or MDXG?
ANGO returned -9.54% over the past 12 months, compared with -54.88% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Are AngioDynamics and MiMedx Group in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.